Conclusion: ChEIs, memantine, and GV-971 all can slow the progression of AD but have different effects on respective assessments. Donepezil and GV-971 were relatively well tolerated.
PubMed 38640313 ↗Donepezil
The short answer. There isn't much data on Donepezil yet — 21 mentions, 4 with a clear outcome — so treat these numbers as anecdotal. It is most often used for memory: 100% of 7 reports say that improved. It is well studied — 221 meta-analyses on PubMed.
From 21 mentions in total — the rest didn't say how it went and aren't counted.
What Donepezil does, according to users
Of the people who reported each effect, the share who said it got better.
4 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 221 meta-analyses on PubMed ↗ · 406 randomized trials ↗
Conclusion: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
PubMed 26085043 ↗Conclusion: Here we show the significant effects of all available acetylcholinesterase inhibitors on cognitive function in patients with AD. However, further studies are needed to draw valid conclusions about the effects of acetylcholinesterase inhibitors on functional outcomes and adverse events.
PubMed 38439609 ↗Conclusion: α-GPC alone or in combination with donepezil improved cognition, behavior, and functional outcomes among patients with neurological conditions associated with cerebrovascular injury.
PubMed 36683513 ↗375 human trials on ClinicalTrials.gov test Donepezil — 251 completed, 15 recruiting now. See all on ClinicalTrials.gov ↗
- Pharmacokinetic Study of GB-5001A 280 mg Long Acting Injection, in Comparison With the Comparator Drug Aricept® 5 mg and Aricept® 10 mg Film-coated Tablet in Healthy Subjects · Bioavailability Study on Healthy Volunteers · 2026
- Progress of Mild Alzheimer's Disease in Participants on Acupuncture Versus Sham Acupuncture · Alzheimer Disease 1 · 2025
- Phenserine on the Alzheimer's Treatment Horizon, Study 1 · Alzheimer Disease, Mild Cognitive Impairment · 2025
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
The current US prescription label has no boxed warning.
5 recalls of products named for Donepezil. Most recent:
- 2024-01-03 · Class II: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. record ↗
- 2021-09-08 · Class III: Subpotent record ↗
- 2017-05-03 · Class III: Supotent: Out of Specification result for assay test during routine stability testing. record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
36,484 adverse-event reports mention Donepezil. Most often reported:
- Fall · 3,094
- Death · 2,135
- Confusional state · 1,968
- Diarrhoea · 1,808
- Dizziness · 1,803
- Fatigue · 1,762
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Donepezil D — a possible rare cause of liver injury (1–3 published cases). LiverTox entry ↗
NIH has funded 20 research projects with Donepezil in the title, $13,176,891 in total (1998–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Donepezil ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“This is by far the number 1 nootropic in the world in my eyes. Nothing even comes close to this one.”
“I think it helps with my overall cognition. It definitely helps with reading comprehension...I take a low dose, however, like 1.25 mg”
“I'm planning on implementing donezeil for its memory benefits... slowly tapering up to 10mg a day.”
Top discussions (5)
- I HAVE TRIED MORE NOOTROPICS THAN YOU. Here are some that I like ↗
- Nootropics that stood the test of time for me ↗
- Modulating Your Dopamine(Beyond Transmission) and Acetylcholine receptors for Maximum Performance (High Risk) ↗
- Peptides to permanently improve cognition? ↗
- stack to slow down progression of dementia? ↗
Donepezil compared
Other options for memory
Sources
- User reports: 21 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate